Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is well-positioned to disrupt the retinal disease treatment market with its innovative therapy, TH103, which has shown early efficacy and has strong patent protection. However, the company faces potential risks in terms of market competition and regulatory restrictions, which must be overcome for the therapy to achieve success and drive the stock price up. Despite the risks, Kalaris' unique therapy has the potential to outperform the current gold standard and bring significant returns for investors in the long run.

Bears say

Kalaris Therapeutics is expected to face significant challenges in the competitive market for anti-VEGF drugs, despite the growing demand for treatments for retinal diseases. While the company's TH103 shows potential for longer-lasting effects, there are concerns about adherence and the need for frequent injections, which may limit its commercial success. Additionally, Kalaris is heavily dependent on the success of TH103, which poses a significant risk to the company's financial performance. With these factors in mind, a negative outlook on Kalaris Therapeutics' stock is justified.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.